Research at Oslo University Hospital

A recent study from the Sections of Core Facilities/Radiation Biology/Tumor Immunology shows that the cell cycle can be completely resolved by mass cytometry, including subdivision of the G₁ and G₂ phases. Only a few markers are needed, and the remaining >50 parameters are free to measure the expression of other (phospho)proteins of interest. Stratification of cells into different cell cycle phases also made exclusion of non-single cell events possible, solving another problem in mass cytometry.

Oslo University Hospital is part of the PERCATHE (Personalised cancer therapies) consortium, aiming to develop new, powerful and frontiers-breaking methods to build an innovative and practicable pipeline for individualised precision treatment of cancer. PERCATHE is one of 14 convergence environments under UiO:Life Science - the largest priority area at UiO.
Consortium members -  OUS and UIO scientists Arnoldo Frigessi, Olav Engebråten,  Vessela Kristensen, Alvaro Köhn Luque and Carl Henrik Gørbitz - have recently published a feature article in the popular science "Knowledge" (Viten) section of the Norwegian major newspaper Aftenposten, entitled "Can statistics and mathematics save as many lives as new medicines?"

The Genetics and Genomics of Cancer meeting takes place at Holmenkollen Scandic Hotel January 27-28 2020. The meeting is organized by Oslo University Hospital, Faculty of Medicine at UiO, Akershus University Hospital,  Vestre Viken Hospital Trust and National Breast Cancer Network. More than 20 international speakers are confirmed.

Oncologist and pathologist from all the University Hospitals in Norway recently gather at the Norwegian Radium Hospital to discuss implementation of personalized medicine in cancer treatment.

The meeting was organized by the Division of Cancer Medicine at OUS to highlight the needs and challenges related to the advanced molecular diagnostics needed for implementation of personalized medicine in both clinic practice and clinical trials.

National cancer screening programs are widely implemented to reduce cancer incidence and mortality in high-income countries, but there is insufficient knowledge of the utility and potential for harmful consequences of this practice. Several of the programs are introduced without the necessary testing of the methods in advance.
This is the topic of professor Mette Kalager and professor Michael Bretthauer's recent article in the prestigious journal Science.

Tuula Nyman is awarded 57 million kroner for her project “National network for advanced proteomic-infrastructrure”, NAPI in short from the Norwegian Research Council.

Nyman is a researcher at the Department for immunology at the Institute of Clinical Medicine at UiO and Oslo University Hospital, and head of the Proteomics Core Facility.

Oslo University Hospital hereby announce research awards in the following two catagories for 2020:

• Excellent Researcher Award (one prize, 300.000 NOK)
• Early Career Award (two prizes of 150.000 NOK each)

Closing date for nominations: March 2nd 2020.

Theodossis Theodossiou, senior researcher and leader of the Protonics project group at the Department of Radiation Biology, has recently been interviewed for the Smithsonian - the official journal published by the Smithsonian Institution in Washington, D.C.
His views on how natural light may be used in future cancer treatment are presented in a feature article entitled "How Studying Bioluminescent Creatures Is Transforming Medical Science".

Dr. Pierre Chymkowitch from the Department of Microbiology at Oslo University Hospital has recently been granted 8.531 million NOK through the FRIPRO program from The Norwegian Research Council.

The “Researcher Project” receiving support is entitled “Regulation of mitotic transcription by centromeres”.